Recently, another essential oncogenic mechanism of RHOA G17V mutations has been revealed: the G17V mutant directly binds to VAV1, a critical intermediate of the TCR pathway, and then aberrantly activates the TCR pathway, and this finding offers insights into AITL development (17, 18). This evidence concerns the gene VAV1 and angioimmunoblastic T-cell lymphoma.